Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±µ¿¸Æ »öÀü¼ú: Áõ»óÀÌ ÀÖ´Â ¾ç¼º Àü¸³¼± ºñ´ëÁõ Ä¡·á Prostate Artery Embolization: Treatment of Symptomatic Benign Prostatic Hyperplasia

´ëÇÑ¿µ»óÀÇÇÐȸÁö 2019³â 80±Ç 4È£ p.656 ~ 666
ȲÁøÈ£, ¹Ú»ó¿ì,
¼Ò¼Ó »ó¼¼Á¤º¸
ȲÁøÈ£ ( Hwang Jin-Ho ) 
°Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¿µ»óÀÇÇб³½Ç

¹Ú»ó¿ì ( Park Sang-Woo ) 
°Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¿µ»óÀÇÇб³½Ç

Abstract

Àü¸³¼±µ¿¸Æ »öÀü¼úÀº ¾ç¼º Àü¸³¼± ºñ´ëÁõÀ¸·Î ÀÎÇÑ ÇϺοä·ÎÁõ»ó °³¼±À» À§ÇÑ »õ·Î¿î Ä¡·á¹æ¹ýÀÌ´Ù. Àü¸³¼±µ¿¸Æ »öÀü¼úÀº Áߵ ¹× ÁßÁõÀÇ ÇϺοä·ÎÁõ»óÀ» º¸À̴ ȯÀÚ¿¡°Ô ÃÖ¼Ò Ä§½ÀÀûÀÎ ¹æ¹ýÀ¸·Î ÁÁÀº °á°ú¸¦ Á¦°øÇÒ ¼ö ÀÖ´Ù. ¾ç¼º Àü¸³¼± ºñ´ëÁõ ȯÀÚÀÇ ´ë´Ù¼ö´Â °í·ÉÀ̸ç, »çÇ༺, Á×»ó °æÈ­¼º ¹× ÀÛÀº Å©±âÀÇ Àü¸³¼± µ¿¸ÆÀº ½Ã¼úÀÇ ³­À̵µ¸¦ ³ôÀÌ´Â ¿øÀÎÀÌ µÇ¹Ç·Î ¼º°øÀûÀÎ °á°ú¸¦ ±â´ëÇϱâ À§Çؼ­´Â ȯÀÚ ¼±ÅÃÀÌ Áß¿äÇÏ´Ù. ¿øÄ¡ ¾Ê´Â ºÎÀ§ÀÇ »öÀü ¾øÀÌ ¾ÈÀüÇÑ ½Ã¼úÀ» ½ÃÇàÇϱâ À§Çؼ­´Â Àü¸³¼±µ¿¸Æ ÇغÎÇп¡ ´ëÇÑ Á¤È®ÇÑ Áö½Ä»Ó¸¸ ¾Æ´Ï¶ó ½Ã¼ú ½Ã ¼¼½ÉÇÑ ±â¼úÀÌ ÇÊ¿äÇÏ´Ù. ÀÎÅͺ¥¼Ç ¿µ»óÀÇÇаú¿Í ºñ´¢±â°ú »çÀÌ¿¡ ±ä¹ÐÇÑ Çù·ÂÀº ´õ ³ªÀº °á°ú¸¦ ¾ò´Â µ¥ À־ µµ¿òÀÌ µÉ ¼ö ÀÖ´Ù.

Prostatic artery embolization (PAE) is an emerging treatment option for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). PAE is a minimally invasive technique and provides good results in BPH patients with moderate-to-severe LUTS. Most patients with BPH are old and have atherosclerosis. PAE can be technically challenging in these patients because of the tortuosity and small diameters of prostatic arteries. Therefore, patient selection is essential for successful results. To perform a safe procedure with no non-target embolization, precise knowledge of the prostatic arterial anatomy and meticulous techniques are important. A multidisciplinary approach by interventional radiologists and urologists is essential to achieve better outcomes.

Å°¿öµå

Embolization, Therapeutic; Arteries; Prostate; Prostatic Hyperplasia; Benign Prostatic Hyperplasia

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS